Profitability Ratios
| Ratio |
Value |
| GP Margin |
78.8% |
| EBIT Margin |
36.8% |
| EBITDA Margin |
46.1% |
| Operating Margin |
39.7% |
| Pretax Margin |
33.3% |
| Cont. Ops Margin |
28.9% |
| Net Margin |
28.9% |
| Bottom Line Margin |
28.9% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
1.68 |
| Quick Ratio |
1.31 |
| Solvency Ratio |
0.310 |
| Cash Ratio |
0.64 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.01 |
| Forward PEG |
0.01 |
| Price/Book |
6.75 |
| Price/Sales |
5.19 |
| Price/FCF |
16.15 |
| Price/Op Cash Flow |
15.24 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.4167 |
| Debt/Equity |
1.0873 |
| Debt/Capital |
0.5209 |
| Long-Term Debt/Capital |
0.5209 |
| Financial Leverage |
2.61 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
3.86 |
| Operating Cash Flow Ratio |
0.848 |
| Operating Cash Flow/Sales |
34.0% |
| Free Cash Flow/Operating Cash Flow |
94.4% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
12.01 |
| Interest Coverage |
11.4268 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
0.41 |
| Capital Expenditure Coverage |
17.80 |
| Dividend + Capital Expenditure Coverage |
2.19 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
47.0388% |
| Dividend Yield |
2.6217% |
| Dividend Yield % |
2.6217% |
| Dividend Per Share |
3.2178 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
23.67 |
| EPS |
6.841 |
| Debt/Share |
20.5916 |
| Cash/Share |
8.52 |
| Book Value/Share |
18.18 |
| Tangible BV/Share |
-2.15 |
| Equity/Share |
18.18 |
| Operating Cash Flow/Share |
8.054 |
| Capital Expenditure/Share |
0.453 |
| FCF/Share |
7.601 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.869 |
| Earnings Before Tax/EBIT |
0.837 |
| Price/Fair Value |
6.75 |
| Debt/Market Cap |
0.1611 |
| Effective Tax Rate |
13.1% |
| Enterprise Value Multiple |
12.50 |
GILD - Gilead Sciences, Inc.